Clinical Trial Update: Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ipilimumab 3 mg/kg vs 10 mg/kg in chemotherapy-naive metastatic castration-resistant prostate cancer; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-07-19